967 related articles for article (PubMed ID: 12827224)
1. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
2. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
[TBL] [Abstract][Full Text] [Related]
3. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
4. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
5. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
Ringe JD; Kipshoven C; Cöster A; Umbach R
Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
[TBL] [Abstract][Full Text] [Related]
6. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen P; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
8. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
9. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.
Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020
[TBL] [Abstract][Full Text] [Related]
10. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
12. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
14. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
[TBL] [Abstract][Full Text] [Related]
15. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
16. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
17. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]